| Literature DB >> 34126898 |
Milica M Borovcanin1, Gordana D Radosavljevic2, Jelena Pantic2, Jelena Milovanovic2, Natasa R Mijailovic3, Aleksandar N Arsenijevic2, Nebojsa N Arsenijevic2.
Abstract
The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a "second hit" later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Cognition; Comorbidity; Galectin-3; Neurodegeneration; Neuroinflammation; Psychosis; Schizophrenia.
Mesh:
Substances:
Year: 2021 PMID: 34126898 DOI: 10.2174/1568026621666210611162420
Source DB: PubMed Journal: Curr Top Med Chem ISSN: 1568-0266 Impact factor: 3.295